Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure

This study has been completed.
University of Aarhus
Aarhus University Hospital
Information provided by:
Aarhus University Hospital Skejby
ClinicalTrials.gov Identifier:
First received: December 9, 2005
Last updated: December 18, 2007
Last verified: December 2007
The purpose of this study is to determine whether 48 hours of glucagon-like-peptide-1 (GLP-1) infusion can improve heart function and alter substrate metabolism in non-diabetic patients with heart failure.

Condition Intervention
Heart Failure, Congestive
Drug: GLP-1
Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of 48 Hours GLP-1 Infusion on Left Ventricular Function, Exercise Capacity, Insulin Sensitivity and Substrate Metabolism in Patients With Chronic Heart Failure

Resource links provided by NLM:

Further study details as provided by Aarhus University Hospital Skejby:

Primary Outcome Measures:
  • Effect on global left ventricular function [ Time Frame: at baseline and after 48 hours of intervention ]
  • Effect on regional left ventricular function [ Time Frame: at baseline and after 48 hours of intervention ]
  • Effect on exercise capacity [ Time Frame: at baseline and after 48 hours of intervention ]
  • Effect on 6 minute walk test [ Time Frame: at baseline and after 48 hours of intervention ]
  • Effect on insulin sensitivity [ Time Frame: after 48 hours of intervention ]
  • Effect on substrate metabolism at whole-body level and in the fore-arm [ Time Frame: after 48 hours of intervention ]

Enrollment: 20
Study Start Date: December 2005
Study Completion Date: December 2007
Arms Assigned Interventions
Active Comparator: 1 Drug: GLP-1
iv. by weight (1.0 pmol/kg/min )
Placebo Comparator: 2 Drug: placebo
same rate of infusion as GLP-1

Detailed Description:

Heart failure is a major complication in patients with ischemic heart disease. It has been shown that many of these patients have areas of viable myocardium that are not effectively contributing to heart function.

Further, chronic congestive heart failure is associated with some degree of insulin resistance in both skeletal and cardiac muscle.

GLP-1 is a naturally occurring peptide hormone that acts as an incretin and has been intensively studied by many groups in association with type II diabetes and it has clearly shown its glucose lowering potential with very little risk of hypoglycemia in several trials.

Recently GLP-1 has been shown to improve cardiac function in dogs with pace-induced cardiomyopathy, and in an open-labeled study it did improve cardiac function in patients with acute myocardial infarctions.

Comparison: 48 hours of treatment with intravenous GLP-1 compared to placebo. Effect on global and regional left ventricular function, exercise capacity, insulin sensitivity and substrate metabolism.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Chronic congestive heart failure
  • Ischemic heart disease

Exclusion Criteria:

  • Diabetes
  • Exercise limiting disease other than heart failure
  • Congenital heart disease
  • Arterio-venous shunts
  • Renal failure
  • Valvular heart disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00264199

Afdeling B, Skejby Hospital
Aarhus, Denmark, 8200
Sponsors and Collaborators
Aarhus University Hospital Skejby
University of Aarhus
Aarhus University Hospital
Principal Investigator: Hans Erik Bøtker, MD Afdeling B, Skejby Hospital
  More Information

Responsible Party: Mads Halbirk, Aarhus University Hospital, Skejby
ClinicalTrials.gov Identifier: NCT00264199     History of Changes
Other Study ID Numbers: 20050048 
Study First Received: December 9, 2005
Last Updated: December 18, 2007
Health Authority: Denmark: The Danish National Committee on Biomedical Research Ethics

Keywords provided by Aarhus University Hospital Skejby:
Chronic Congestive heart failure
Ischemic heart disease
insulin resistance

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases

ClinicalTrials.gov processed this record on May 24, 2016